1
|
Bravo B, Argüello JM, Forriol F, Altónaga JR. [Translated article] Infrapatellar fat pad resection effect on the osteoarthritis development: Experimental study in sheep. Rev Esp Cir Ortop Traumatol (Engl Ed) 2024; 68:T134-T141. [PMID: 37992862 DOI: 10.1016/j.recot.2023.11.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 05/09/2023] [Indexed: 11/24/2023] Open
Abstract
INTRODUCTION The fat of the synovial joints can be used to maintain the joint structure. Our objective is to analyse the evolution of joint degeneration in knees with and without adipose pack. MATERIAL AND METHODOLOGY In six sheep, the anterior cruciate ligament was sectioned in both knees, to cause osteoarthritis. In one group the fat pack was preserved and in another group it was completely removed. We performed a histological and molecular biology study analyzing the expression, in the synovial membrane, subchondral bone, cartilage, fat, meniscus, and synovial fluid, of RUNX2, PTHrP, cathepsin-K, and MCP1. RESULTS We did not find morphological differences. We found increased expression of RUNX2 in synovial membrane, PTHrP and Cathepsin K in synovial fluid in the group without fat, and increased expression of RUNX2 in the meniscus and MCP1 in synovial fluid in the group with fat. CONCLUSION Infrapatellar fat participates in the inflammatory process that accompanies osteoarthritis, since Hoffa fat pad resection alters pro-inflammatory markers, while the model with intact fat increases the pro-inflammatory marker MCP1 in synovial fluid.
Collapse
Affiliation(s)
- B Bravo
- Departamento de Ciencias Básicas, Facultad de Medicina, Universidad CEU-San Pablo, Madrid, Spain.
| | - J M Argüello
- Servicio de Cirugía Ortopédica y Traumatología, Fundación Jiménez Díaz, Madrid, Spain
| | - F Forriol
- Departamento de Ciencias Básicas, Facultad de Medicina, Universidad CEU-San Pablo, Madrid, Spain
| | - J R Altónaga
- Clínica Veterinaria, Facultad de Veterinaria, Universidad de León, León, Spain
| |
Collapse
|
2
|
Bravo B, Argüello JM, Forriol F, Altónaga JR. Infrapatellar Fat Pad resection effect on the osteoarthritis development: Experimental study in sheep. Rev Esp Cir Ortop Traumatol (Engl Ed) 2024; 68:134-141. [PMID: 37187343 DOI: 10.1016/j.recot.2023.05.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 05/08/2023] [Accepted: 05/09/2023] [Indexed: 05/17/2023] Open
Abstract
INTRODUCTION The fat of the synovial joints can be used to maintain the joint structure. Our objective is to analyze the evolution of joint degeneration in knees with and without adipose pack. MATERIAL AND METHODOLOGY In six sheep, the anterior cruciate ligament was sectioned in both knees, to cause osteoarthritis. In one group the fat pack was preserved and in another group it was completely removed. We performed a histological and molecular biology study analyzing the expression, in the synovial membrane, subchondral bone, cartilage, fat, meniscus, and synovial fluid, of RUNX2, PTHrP, cathepsin-K, and MCP1. RESULTS We did not find morphological differences. We found increased expression of RUNX2 in synovial membrane, PTHrP and Cathepsin K in synovial fluid in the group without fat, and increased expression of RUNX2 in the meniscus and MCP1 in synovial fluid in the group with fat. CONCLUSION Infrapatellar fat participates in the inflammatory process that accompanies osteoarthritis, since Hoffa fat pad resection alters pro-inflammatory markers, while the model with intact fat increases the pro-inflammatory marker MCP1 in synovial fluid.
Collapse
Affiliation(s)
- B Bravo
- Departamento de Ciencias Básicas, Facultad de Medicina, Universidad CEU-San Pablo, Madrid, España.
| | - J M Argüello
- Servicio de Cirugía Ortopédica y Traumatología, Fundación Jiménez Díaz, Madrid, España
| | - F Forriol
- Departamento de Ciencias Básicas, Facultad de Medicina, Universidad CEU-San Pablo, Madrid, España
| | - J R Altónaga
- Clínica Veterinaria, Facultad de Veterinaria, Universidad de León, León, España
| |
Collapse
|
3
|
Prieto-Peña D, Loricera J, Castañeda S, Moriano C, Bernabéu P, Vela-Casasempere P, Narváez J, Aldasoro V, Maíz O, Fernández-López C, Freire González M, Melero R, Villa-Blanco I, González-Alvarez B, Solans-Laqué R, Callejas-Rubio JL, Fernández-Díaz C, Rubio Romero E, García Morillo S, Minguez M, Fernández-Carballido C, De Miguel E, Sanchez-Martin J, Fernández E, Melchor S, Salgado-Pérez E, Bravo B, Romero-Yuste S, Galíndez-Agirregoikoa E, Sivera F, Ferraz-Amaro I, Hidalgo C, Romero-Gómez C, Galisteo C, Moya P, Alvarez-Rivas N, Mendizabal J, Nieto González JC, De Dios JR, Andreu JL, Pérez de Pedro I, Revenga M, Alonso Valdivieso JL, Rosa RM, De la Morena I, Fernández-Llanio N, Labrador E, Roman-Ivorra JA, Ortiz-Sanjuán F, García-Valle A, Gallego A, Iñiguez C, Garrido-Puñal N, De la Torre R, López-González R, Collado P, Raya E, Navarro F, Mas AJ, Ordás C, Boquet MD, Velloso Feijoo ML, Campos Fernández C, Rúa-Figueroa I, Conesa A, Manrique Arija S, González-Gay MA, Blanco R. POS0804 TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundTocilizumab (TCZ) has shown to be effective for large vessel vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK) (1-5). However, LVV-GCA and TAK show different demographic and clinical features that may influence on TCZ therapeutic response.ObjectivesTo compare the effectiveness of TCZ in patients with LVV-GCA and patients with TAK.MethodsObservational multicenter study of patients with LVV-GCA and TAK who received TCZ. Outcome variables were: a) proportion of patients who achieved complete clinical improvement along with normalization of laboratory markers (CRP ≤0.5mg/dL and/or ESR ≤ 20 mm/1st hour) at 12 months b) complete improvement in imaging techniques. A comparative study between patients with LVV-GCA and TAK was performed.ResultsWe evaluated 70 LVV-GCA and 57 TAK patients who received TCZ. Main clinical and demographic characteristic are described in Table 1. Patients with TAK were younger, had longer disease duration, had received more commonly previous biologic therapy and were receiving higher doses of prednisone at baseline. TCZ intravenous administration was more common in TAK patients (80.7% vs 48.6%; p<0.01). Follow-up time after TCZ onset was similar in both groups. At 12 months, about 75% of patients achieved complete clinical improvement and ESR/CRP normalization in both groups. A follow-up imaging technique was performed in 37 LVV-GCA patients after a mean time of 12.9±6.0 months and 38 TAK patients after 9.5±5.0 months. Complete improvement in imaging techniques was only observed in 18.9% and 21.1% of patients with LVV-GCA and TAK, respectively (Figure 1).Table 1.LVV-GCA (n=70)TAK (n=57)pGeneral featuresAge (years), mean ± SD67.2 ± 10.540.5 ± 16.3< 0.01Sex (female), n (%)51 (72.9)49 (86)0.07Disease evolution before TCZ onset (months), median [IQR]5 [2-15]12 [3-37]<0.01Baseline laboratory parametersESR (mm/1st hour), median [IQR]32 [12.5-54.7]31 [10-52]0.82CRP (mg/dL), median [IQR]1.4 [0.5-2.4]1.4 [0.5-3.5]0.41Baseline prednisone dose (mg/day), median [IQR]15 [10-20]30 [15-50]< 0.01Previous therapyConventional DMARDs, n(%)45 (64.3)44(77.2)0.51Biologic therapy, n (%)0(0)12 (21.1)<0.01TCZ therapyIntravenous, n (%)34 (48.6)46 (80.7)< 0.01Combined with MTX, n(%)24 (34.3)24 (42.1)0.37Follow-up time after TCZ onset, median [IQR]20 [10-36]18 [7-41]0.73Complete clinical improvement and ESR/CRP normalization at 12 months, n/N (%)35/47 (74.4)30/39 (76.9)0.79Complete improvement in imaging techniques, n/N(%)7/37 (18.9)8/38 (21.1)0.85CRP: C-reactive protein; DMARDs: Disease-modifying anti-rheumatic drugs ESR: erythrocyte sedimentation rate; GCA: giant cell arteritis; IQR: interquartile range; LVV: large vessel; MTX: methotrexate; n: Number of patients; N: total number of patients: TCZ: tocilizumab; TAK:takayasuFigure 1.ConclusionThe effectiveness of TCZ was similar in patients with LVV-GCA and TAK, despite a more refractory disease in TAK patients. A discordance between clinical and imaging activity improvement was observed in both LVV-GCA and TAK, as reported in previous studies (3).References[1]Calderón-Goercke M, et al. Semin Arthritis Rheum 2019; 49:126-35. https://doi.org/10.1016/j.semarthrit.2019.01.003[2]Prieto-Peña D et al. Ther Adv Musculoskelet Dis. 2021;13:175. PMID: 34211589.[3]Prieto Peña D et al. Clin Exp Rheumatol. 2021;39 Suppl 129:69-75. PMID: 33253103.[4]González-Gay MA, et al. Expert Opin Biol Ther. 2019;19:65-72. doi: 10.1080/14712598.2019.1556256.[5]Prieto-Peña D, et al. Semin Arthritis Rheum. 2019;48(4):720-727. doi: 10.1016/j.semarthrit.2018.05.007Disclosure of InterestsNone declared
Collapse
|
4
|
Prieto-Peña D, Bernabéu P, Vela-Casasempere P, Narváez J, Fernández-López C, Freire González M, González-Alvarez B, Solans-Laqué R, Callejas-Rubio JL, Ortego N, Fernández-Díaz C, Rubio Romero E, García Morillo S, Minguez M, Fernández-Carballido C, De Miguel E, Melchor S, Salgado-Pérez E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique Arija S, Romero-Gómez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz Sanjuan FM, Pérez de Pedro I, Alonso Valdivieso JL, Laura PS, Rosa RM, Fernández-Llanio N, Gómez de la Torre R, Suarez S, Montesa MJ, Delgado Sanchez M, Loricera J, Atienza-Mateo B, Castañeda S, González-Gay MA, Blanco R. AB0366 TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.1747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Tocilizumab (TCZ) has shown to be effective for large vessel vasculitis including Takayasu arteritis (TAK) (1-3). Most evidence in TAK comes from Asian patients. However, white patients seem to have different clinical and prognostic features.Objectives:Our aims were to: a) assess the efficacy and safety of TCZ in white patients with refractory TAK, b) determine if clinical improvement correlates with imaging outcomes, c) compare TCZ in monotherapy (TCZMONO) vs combined with conventional immunosuppressive drugs (TCZCOMBO)Methods:Multicenter study of white patients with refractory TAK who received TCZ.Outcomes variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZMONO and TCZCOMBO was performed.Results:54 patients (46 women/8 men; median age 42.0 [32.5-50.5] years). TCZ was started after 12.0 [3.0-31.5] months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%) and 27/36 (75%) at 1, 3, 6 and 12 months, respectively. Prednisone dose was reduced from 30.0 [12.5-50.0] to 5.0 [0.0-5.6] mg/day at 12 months (Table 1). 10 (26.3%) of the 38 patients in whom an imaging follow-up test was performed showed no radiographic improvement after a median of 9.0 [6.0-14.0] months. 4 of them were in clinical remission.23 (42.6%) patients were on TCZMONO and 31 (57.4%) on TCZCOMBO: MTX (n=28), cyclosporine A (n=2), azathioprine (n=1). Patients on TCZCOMBO were younger (38.0 [27.0-46.0] vs 45 [38.0-57.0] years; p= 0.048), with a trend to longer TAK duration (21.0 [6.0-38.0] vs 6.0 [1.0-23.0] months; p= 0.08) and higher C-reactive protein (2.4 [0.7-5.6] vs 1.3 [0.3-3.3] mg/dL; p=0.16). Despite these differences, similar outcomes were observed in both groups (log rank p=0.862) (Figure 1). Relevant adverse events were reported in 6 (11.1%) patients, but only 3 developed severe events that required TCZ withdrawal.Table 1.Baselinen=54Month 1N=54Month 3N=49Month 6N=44Month 12N=36Clinical remission, n (%)12 (22.2)19 (38.8)23 (52.3)27 (75.0)Laboratory improvementCRP (mg/dL), median [IQR]1.5 [0.5-3.5]0.2 [0.1-0.7]*0.2 [0.5-0.5]*0.2 [0.1-0.5]*0.1 [0.0-0.4]*ESR (mm/1sthour), median [IQR]30.5 [8.7-52.7]7.0 [3.0-14.0]*4.5 [2.0-8.0]*5.0[2.0-6.0]*4.0 [2.0-9.5]*Hemoglobin (g/dL), mean ± SD12.4 ±1.513.0 ±1.2*13.0 ±1.4*13.2 ±1.5*12.9 ±1.6*Prednisone dose, median [IQR]30.0 [12.5-50.0]20.0 [10.0-30.0]*10.0 [5.0-20.0]*5.0 [5.0-10.5]*5.0 [0.0-5.6]*CRP: C-Reactive Protein; ESR: Erythrocyte Sedimentation Rate; IQR: interquartile range; n: number. *p<0.01 vs baseline (Wilcoxon test).Conclusion:TCZ is effective and safe in white patients with refractory TAK. A discordance between clinical and imaging activity assessment may exist.References:[1]Prieto Peña D et al. Clin Exp Rheumatol 2020 Nov 27. PMID: 33253103.[2]Loricera J, et al. Clin Exp Rheumatol 2016; 34:S44-53. PMID: 27050507.[3]Calderón-Goercke M, et al. Semin Arthritis Rheum 2019; 49:126-35. PMID: 30655091Disclosure of Interests:Diana Prieto-Peña Grant/research support from: DP-P has received research support from UCB Pharma, Roche, Sanofi, Pfizer, AbbVie and Lilly., Pilar Bernabéu: None declared, Paloma Vela-Casasempere: None declared, J. Narváez: None declared, Carlos Fernández-López: None declared, Mercedes Freire González: None declared, Beatriz González-Alvarez: None declared, Roser Solans-Laqué: None declared, Jose Luis Callejas-Rubio: None declared, Norberto Ortego: None declared, Carlos Fernández-Díaz: None declared, Esteban Rubio Romero: None declared, SALVADOR GARCÍA MORILLO: None declared, Mauricio Minguez: None declared, Cristina Fernández-Carballido: None declared, Eugenio de Miguel: None declared, Sheila Melchor: None declared, Eva Salgado-Pérez: None declared, Beatriz Bravo: None declared, Susana Romero-Yuste: None declared, Juan Salvatierra: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, C. Romero-Gómez: None declared, Patricia Moya: None declared, Noelia Alvarez-Rivas: None declared, Javier Mendizabal: None declared, Francisco Miguel Ortiz Sanjuan: None declared, I. Pérez de Pedro: None declared, JOSE LUIS ALONSO VALDIVIESO: None declared, Pérez Sánchez Laura: None declared, Roldán Molina Rosa: None declared, Nagore Fernández-Llanio: None declared, Ricardo Gómez de la Torre: None declared, Silvia Suarez: None declared, María Jesús Montesa: None declared, Monica Delgado Sanchez: None declared, J. Loricera: None declared, Belén Atienza-Mateo: None declared, Santos Castañeda: None declared, Miguel A González-Gay Grant/research support from: MAG-G received grants/research supports from Abbvie, MSD, Jansen and Roche and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Pfizer, Roche, Sanofi, Lilly, Celgene and MSD, Ricardo Blanco Grant/research support from: RB received grants/research supports from Abbvie, MSD and Roche, and had consultation fees/participation in company sponsored speaker´s bureau from Abbvie, Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD.
Collapse
|
5
|
Prieto-Peña D, Calderón-Goercke M, Bernabéu P, Vela-Casasempere P, Narváez J, Fernández-López C, Freire González M, González-Alvarez B, Solans-Laqué R, Callejas-Rubio JL, Ortego N, Fernández-Díaz C, Rubio Romero E, García Morillo S, Minguez M, Fernández-Carballido C, De Miguel E, Melchor S, Salgado-Pérez E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique Arija S, Romero-Gómez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz Sanjuan FM, Pérez de Pedro I, Loricera J, Castañeda S, González-Gay MA, Blanco R. SAT0270 TOCILIZUMAB IN REFRACTORY TAKAYASU ARTERITIS. OPEN-LABEL NATIONAL MULTICENTER STUDY OF 53 PATIENTS OF CLINICAL PRACTICE. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2445] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Tocilizumab (TCZ) was recently approved for Takayasu Arteritis (TAK) in Japan based on the results of the TAKT trial(1).However, data in clinical practice in Europe and America are scarce(2).Objectives:To assess efficacy and safety of TCZ in TAK of clinical practice in Spain.Methods:Observational, open-label multicentre study of 53 TAK patients treated with TCZ due to refractoriness or adverse events of previous therapy. Outcomes variables were improvement of clinical features, acute phase reactants and glucocorticoid-sparing effect.Results:53 patients (46w/7m); mean age, 40.6±14.6 years at TCZ onset. TCZ was started after a median of 12 [3.0-48.0] months from TAK diagnosis. In addition to systemic corticosteroids and before TCZ they received conventional immunosuppressant drugs (n=42) and biologic therapy (n=14). TCZ was prescribed as standard I.V. (n=42; 79.2%) or subcutaneous (n=11; 20.8%). The initial dose was 8 mg/kg/IV/4 weeks or 162 mg/SC/week, respectively. TCZ was used in monotherapy or combined with immunosuppressants (n=32; 60.4%): methotrexate (n=27), azathioprine (n=2), cyclosporine (n=3). Main clinical features at TCZ onset were: malaise (n=30),limb claudication (n=22), headache (n=18), fever (n=14), abdominal pain (n=10), and chest pain (n=9). Most of the patients experienced a rapid and maintained clinical, analytical improvement(TABLE).After a median follow-up of 18.0 [7.0-45.0] months, TCZ was discontinued in 20 patients due to: sustained remission (n=6), relapse (n=6), adverse event (n=5), gestation (n=3). Most relevant adverse side effects were serious infections: pneumonia (n=2), herpes zoster (n=1), abdominal sepsis (n=1).Table.Basal(N=53)Month 1(N=53)Month 3(N=46)Month 6(N=44)Month 12(N=34)Clinical improvement, n/N(%)Complete17/53 (32.1)19/46 (41.3)23/44 (52.3)26/34 (76.5)Partial30/53 (54.6)26/46 (56.5)18/44 (40.9)8/34 (23.5)No improvement6/53 (11.3)1/46 (2.2)3/44 (6.8)0/34 (0.0)Analytical markers,ESR (mm/1sth),median [IQR]35.0 [16.0-52.0]7.5 [3.0-14.0] *3.5 [2.0-8.0]*5.0[2.0-6.0]*5.0 [2.0-8.5]*CRP (mg/dL),median [IQR]1.7 [0.6 -3.5]0.21 [0.05-0.6]*0.14 [0.05-0.5]*0.14 [0.04-0.4]*0.10 [0.03-0.30]*Hb (g/dL),mean±SD12.3±1.512.8±1.2*12.9±1.3*12.9±1.4*12.9±1.4*Prednisone dose (mg/day),median [IQR]30.0 [15.0-50.0]20.0 [10.0-37.5]*10.0 [5.0-20.0]*5.0 [5.0-12.5]*5.0 [0.0-7.5]**Wilcoxon test p < 0.001.Conclusion:TCZ appears to be effective and safe in patients with refractory TAK in clinical practice.References:[1]Nakaoka Y et al. Ann Rheum Dis. 2018;77:348-354[2]Loricera J et al. Clin Exp Rheumatol. 2016; 34: S44-53.Disclosure of Interests:D. Prieto-Peña: None declared, Monica Calderón-Goercke: None declared, Pilar Bernabéu: None declared, Paloma Vela-Casasempere: None declared, J. Narváez: None declared, Carlos Fernández-López: None declared, Mercedes Freire González: None declared, Beatriz González-Alvarez: None declared, Roser Solans-Laqué: None declared, Jose Luis Callejas-Rubio: None declared, Norberto Ortego: None declared, Carlos Fernández-Díaz Speakers bureau: Brystol Meyers Squibb, Esteban Rubio Romero: None declared, SALVADOR GARCÍA MORILLO: None declared, Mauricio Minguez: None declared, Cristina Fernández-Carballido Consultant of: Yes, I have received fees for scientific advice (Abbvie, Celgene, Janssen, Lilly and Novartis), Speakers bureau: Yes, I have received fees as a speaker (Abbvie, Celgene, Janssen, Lilly, MSD, Novartis), Eugenio de Miguel Grant/research support from: Yes (Abbvie, Novartis, Pfizer), Consultant of: Yes (Abbvie, Novartis, Pfizer), Paid instructor for: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Speakers bureau: yes (AbbVie, Novartis, Pfizer, MSD, BMS, UCB, Roche, Grunental, Janssen, Sanofi), Sheila Melchor: None declared, Eva Salgado-Pérez: None declared, Beatriz Bravo: None declared, Susana Romero-Yuste: None declared, J Salvatierra: None declared, Cristina Hidalgo: None declared, Sara Manrique Arija: None declared, C. Romero-Gómez: None declared, Patricia Moya: None declared, Noelia Alvarez-Rivas: None declared, Javier Mendizabal: None declared, Francisco Miguel Ortiz Sanjuan: None declared, I. Pérez de Pedro: None declared, Javier Loricera: None declared, Santos Castañeda: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Ricardo Blanco Grant/research support from: AbbVie, MSD, Roche, Consultant of: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma and MSD, Speakers bureau: Abbvie, Eli Lilly, Pfizer, Roche, Bristol-Myers, Janssen, UCB Pharma. MSD
Collapse
|
6
|
Lebacq A, Saizu M, Takahashi M, Isaksson M, Bravo B, Brose J, Csizmadia L, Fojtík P, Kövendiné-Kónyi J, Lünendonk G, Meisenberg O, Mosimann N, Osko J, Pantya A, Saurat D, Taba G, Torvela T, Vagfoldi Z, Vilardi I, Vu I, Youngman M, Zoriy P, Beaumont T, Franck D, Broggio D. European intercomparison on the measurement of l-131 in thyroid of adults and children. RADIAT MEAS 2019. [DOI: 10.1016/j.radmeas.2019.106178] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
7
|
Bravo B, Arguello JM, Rodríguez-De Gortazar A, Forriol F, Vaquero J. [Pro-inflammatory cytokines in the knee fat pad and subcutaneous fat of the thigh in osteoarthritic patients]. Acta Ortop Mex 2019; 33:204-210. [PMID: 32246589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
OBJECTIVE To analyze the level of pro-inflammatory cytokines in osteoarthritis knee joint fat pad in relation to the subcutaneous fat of the thigh. MATERIAL AND METHODS We performed a study of fat of the knee joint adipose affected of osteoarthritis and subcutaneous fat of the thigh of the same side to the greater distance of the joint in six patients with severe gonarthrosis, with a mean age of 68 years (range: 55-81 years). From the fat samples the progenitor mesenchymal cells were obtained. The supernatants of mesenchymal cells obtained to analyze inflammatory factors (IL-1b, IL6, IL9, IL1ra, IL12, IL13, IL15) and angiogenic (VEGF, PDGF bb) and immunomodulatory cytokines (IP-10 and INF-) means of two samples. RESULTS Quantitative analysis revealed a significant (p 0.05) decrease in IL-1b, IL6, IL8, IL9, IL1ra, IL12, IL13 and increase of IL15 in Hoffa fat pad versus subcutaneous adipose tissue. Likewise, the analysis of angiogenic factors such as VEGF and PDGF, as well as factors IP-10 and INF- presented a significant decrease (p 0.05) in Hoffa fat pad versus subcutaneous adipose tissue. DISCUSSION Mesenchymal cells from the adipose tissue of the severe osteoarthritic knee show a significant decrease in inflammatory cytokines even in the chronic state and a significant decrease in angiogenic factors and immunomodulatory cytokines (IP10 and INF).
Collapse
Affiliation(s)
- B Bravo
- Universidad San Pablo-CEU, Facultad de Medicina, IMMA (Instituto de Medicina Molecular Aplicada), Boadilla del Monte, Madrid. España
| | - J M Arguello
- Fundación Jiménez Díaz, Servicio de Ortopedia y Traumatología, Madrid. España
| | - A Rodríguez-De Gortazar
- Universidad San Pablo-CEU, Facultad de Medicina, IMMA (Instituto de Medicina Molecular Aplicada), Boadilla del Monte, Madrid. España
| | - F Forriol
- Universidad San Pablo-CEU, Facultad de Medicina, IMMA (Instituto de Medicina Molecular Aplicada), Boadilla del Monte, Madrid. España
| | - J Vaquero
- Hospital Universitario Gregorio Marañón, Madrid. España
| |
Collapse
|
8
|
Cadenas Martín M, Tirado I, Martín E, Ardura JA, Bravo B, Gortazar AR. Efectos de la estimulación mecánica en la comunicación entre células óseas. Rev Osteoporos Metab Miner 2019. [DOI: 10.4321/s1889-836x2019000100003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
9
|
Bravo B, Fernández de Castro L, Buendía I, Santos X, Gortázar A. El factor de crecimiento endotelial vascular (VEGF) y el fragmento N-terminal de la proteína relacionada con la parathormona (PTHrP) regulan la proliferación de células madre mesenquimales humanas. Rev Osteoporos Metab Miner 2017. [DOI: 10.4321/s1889-836x2019000100002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
10
|
Maycas M, Fernández de Castro L, Bravo B, García de Durango C, Forriol F, R. Gortázar A, Esbrit P. El receptor 2 de VEGF (VEGFR2) y el receptor 1 de la PTH (PTH1R) actúan como mediadores de la respuesta anti-apoptótica al estímulo mecánico en las células osteocíticas MLO-Y4. Rev Osteoporos Metab Miner 2015. [DOI: 10.4321/s1889-836x2015000400003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
11
|
Palmou-Fontana N, Loricera J, Blanco R, Hernández J, Castañeda S, Humbría A, Ortego N, Bravo B, Freire M, Melchor S, Mínguez M, Salvatierra J, González-Vela C, Calvo-Río V, Pina T, González-Gay M. THU0290 Efficacy and Safety of Tocilizumab in Eight Patients with Takayasu Arteritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
12
|
Palmou-Fontana N, Loricera J, Blanco R, Hernández J, Castañeda S, Ortego N, Peirό E, Collado P, Melchor S, Mera A, Pérez-Pampín E, Rubio E, Calvo-Alén J, Aurrecoechea E, Rúa-Figueroa Í, Mínguez M, Herrero-Beaumont G, Bravo B, Rosas J, Narváez J, Calvo-Catalá J, Ariza R, Freire M, Lluch P, Mata C, Galíndez-Aguirregoikoa E, Blanco-Madrigal J, Sánchez-Andrade A, Salvatierra J, Calvo-Río V, González-Vela C, Pina T, González-Gay M. FRI0270 Tocilizumab Compared to Anti-TNFα Agents in Refractory Aortitis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
13
|
Santos Gόmez M, Calvo-Río V, Blanco R, Calvo I, Maíz O, Atanes A, Bravo B, Modesto C, Díaz Soriano G, Riancho-Zarrabeitia L, Palmaou-Fontana N, González-Gay MΆ. THU0523 Tocilizumab in Refractory Uveitis Associated to Juvenile Idiopathic Arthritis. Multicenter Study of 13 Cases. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5617] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
14
|
González-García C, Bravo B, Ballester A, Gómez-Pérez R, Eguiluz C, Redondo M, Martínez A, Gil C, Ballester S. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis. Br J Pharmacol 2014; 170:602-13. [PMID: 23869659 DOI: 10.1111/bph.12308] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2013] [Revised: 07/01/2013] [Accepted: 07/08/2013] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND AND PURPOSE PDE4 inhibition suppresses experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). However, side effects hinder PDE4 inhibitors clinical use. PDE7 inhibition might constitute an alternative therapeutic strategy, but few data about the anti-inflammatory potential of PDE7 inhibitors are currently available. We have used the EAE model to perform a comparative evaluation of PDE4 and PDE7 inhibition as strategies for MS treatment. EXPERIMENTAL APPROACH Two PDE7 inhibitors, the sulfonamide derivative BRL50481 and the recently described quinazoline compound TC3.6, were assayed to modulate EAE in SJL mice, in comparison with the well-known PDE4 inhibitor Rolipram. We evaluated clinical signs, presence of inflammatory infiltrates in CNS and anti-inflammatory markers. We also analysed the effect of these inhibitors on the inflammatory profile of spleen cells in vitro. KEY RESULTS TC3.6 prevented EAE with efficacy similar to Rolipram, while BRL50481 had no effect on the disease. Differences between both PDE7 inhibitors are discussed. Data from Rolipram and TC3.6 showed that PDE4 and PDE7 inhibition work through both common and distinct pathways. Rolipram administration caused an increase in IL-10 and IL-27 expression which was not found after TC3.6 treatment. On the other hand, both inhibitors reduced IL-17 levels, prevented infiltration in CNS and increased the expression of the T regulator cell marker Foxp3. CONCLUSIONS AND IMPLICATIONS These results provide new information about the effects of Rolipram on EAE, underline PDE7 inhibition as a new therapeutic target for inflammatory diseases and show the value of TC3.6 to prevent EAE, with possible consequences for new therapeutic tools in MS.
Collapse
Affiliation(s)
- C González-García
- Unidad de Regulación Génica, UFIEC, Instituto de Salud Carlos III, Madrid, Spain
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Ortiz Sanjuán F, Beltrán-Catalán E, Calvo-Río V, Blanco R, Calvo I, Hernández-Garfella M, Atanes A, Linares L, Maíz O, Bravo B, Díaz G, Loricera J, Pina T, González-Gay M. THU0391 Efficacy of TOCILIZUMAB in Patients with Refractory Uveitis to Other Biologic Therapy. Multicenter Study of 20 Cases. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
16
|
Loricera J, Blanco R, Castañeda S, Humbría A, Ortego-Centeno N, Narváez J, Mata C, Melchor S, Aurrecoechea E, Calvo-Alén J, Lluch P, Moll C, Mínguez M, Herrero-Beaumont G, Bravo B, Rubio E, Freire M, Peirό E, González-Vela M, Rueda-Gotor J, Pina T, Calvo-Río V, Ortiz-Sanjuán F, González-Gay M. SAT0279 Tocilizumab in Refractory Aortitis: Study on 16 Patients and Literature Review. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2984] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Sposetti CN, Bravo B, Trumper AE, Gazza CJ, Manuel LO. Classical antiferromagnetism in kinetically frustrated electronic models. Phys Rev Lett 2014; 112:187204. [PMID: 24856719 DOI: 10.1103/physrevlett.112.187204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/23/2013] [Indexed: 06/03/2023]
Abstract
We study, by means of the density matrix renormalization group, the infinite U Hubbard model--with one hole doped away from half filling--in triangular and square lattices with frustrated hoppings, which invalidate Nagaoka's theorem. We find that these kinetically frustrated models have antiferromagnetic ground states with classical local magnetization in the thermodynamic limit. We identify the mechanism of this kinetic antiferromagnetism with the release of the kinetic energy frustration, as the hole moves in the established antiferromagnetic background. This release can occur in two different ways: by a nontrivial spin Berry phase acquired by the hole, or by the effective vanishing of the hopping amplitude along the frustrating loops.
Collapse
Affiliation(s)
- C N Sposetti
- Instituto de Física Rosario (CONICET) and Universidad Nacional de Rosario, Boulevard 27 de Febrero 210 bis, (2000) Rosario, Argentina
| | - B Bravo
- Instituto de Física Rosario (CONICET) and Universidad Nacional de Rosario, Boulevard 27 de Febrero 210 bis, (2000) Rosario, Argentina
| | - A E Trumper
- Instituto de Física Rosario (CONICET) and Universidad Nacional de Rosario, Boulevard 27 de Febrero 210 bis, (2000) Rosario, Argentina
| | - C J Gazza
- Instituto de Física Rosario (CONICET) and Universidad Nacional de Rosario, Boulevard 27 de Febrero 210 bis, (2000) Rosario, Argentina
| | - L O Manuel
- Instituto de Física Rosario (CONICET) and Universidad Nacional de Rosario, Boulevard 27 de Febrero 210 bis, (2000) Rosario, Argentina
| |
Collapse
|
18
|
Vargas-Diez E, Hofmann M, Bravo B, Malgazhdarova G, Katkhanova O, Yutzcovskaya Y. Azelaic Acid in the Treatment of Acne in Adult Females: Case Reports. Skin Pharmacol Physiol 2014; 27 Suppl 1:18-25. [DOI: 10.1159/000354889] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
19
|
Loricera J, Blanco R, Castañeda S, Umbría A, Melchor S, Rubio E, Calvo-Alen J, Aurrecoechea E, Rúa-Figueroa I, Ortego N, Minguez M, Herrero-Beaumont G, Bravo B, Rosas J, Narvaez J, Calvo J, Ariza R, Freire M, Lluch P, Moll C, Peiró E, Calvo-Río V, Ortiz-Sanjuán F, González-Gay M. AB0464 Biologic therapy in aortitis: a multicenter study of 30 patients. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2013-eular.2786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
Bou R, García de Vicuña C, Calvo I, Nuñez E, Bravo B, Camacho M, Bustabad S, Rúa M, Solís P, Calvo C, Hernandez V, Carmona L, Antόn J. AB1192 Epidemiology of juvenile idiopathic artritis-associated uveitis in spain: Results from a national registry. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Bravo B, Márquez N, Ysambertt F, Chávez G, Cáceres A, Bauza R, Graciaa A, Lachaise J, Salager JL. Phase behavior of fatty acid/oil/water systems: Effect of the alkyl length chain acid. J SURFACTANTS DETERG 2006. [DOI: 10.1007/s11743-006-0383-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
22
|
Ysambertt F, Subero N, Chávez G, Bravo B, Bauza R, Márquez N. Molecular Weight and EON Distribution of Industrial Polyethoxylated Surfactants by High Performance Size Exclusion Chromatography. SEP SCI TECHNOL 2005. [DOI: 10.1081/ss-200041089] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
23
|
Márquez N, Bravo B, Ysambertt F, Chávez G, Subero N, Salager J. Analysis of polyethoxylated surfactants in microemulsion-oil–water systems. Anal Chim Acta 2003. [DOI: 10.1016/s0003-2670(02)01407-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Márquez N, Gonzalez S, Subero N, Bravo B, Chavez G, Bauza R, Ysambertt F. Isolation and characterization of petroleum sulfonates. Analyst 1998. [DOI: 10.1039/a805810e] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
25
|
Bravo LA, Canut JA, Pascual A, Bravo B. Comparison of the changes in facial profile after orthodontic treatment, with and without extractions. Br J Orthod 1997; 24:25-34. [PMID: 9088600 DOI: 10.1093/ortho/24.1.25] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
A study was made of 31 patients with Angle Class II malocclusion. Fifteen patients did not undergo extraction of teeth (Group A), while 16 underwent extractions of four premolars (Group B). Data was obtained from the corresponding lateral radiographs of the head taken both before and after orthodontic treatment. The main aim of the study was to compare the response of the soft and hard tissues of the facial profile in Class II malocclusion treated with the extraction of four premolars and the response of borderline cases presenting with similar malocclusions, but not subjected to extraction. In this latter group reasonable doubt existed as to whether or not to remove teeth in order to solve the occlusal and aesthetic problems. It is concluded that significant hard tissue differences between the groups at the end of treatment were limited to a more retruded position of the incisors and a reduced overbite amongst those patients subjected to extraction. The main soft tissue differences between the groups at the end of treatment were a more retruded lower lip and a more pronounced lower labial sulcus in those patients subjected to extraction.
Collapse
Affiliation(s)
- L A Bravo
- Orthodontic Unit, School of Medicine, University of Murcia, Spain
| | | | | | | |
Collapse
|
26
|
Mulgaonkar S, Jacobs MG, Viscuso R, Lyman N, Klein P, Bravo B, Clavello A, Filippone D, Dembner A. Laparoscopic internal drainage of lymphocele in renal transplant. Am J Kidney Dis 1992; 19:490-2. [PMID: 1533992 DOI: 10.1016/s0272-6386(12)80960-7] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Lymphoceles frequently develop following renal transplant surgery. The conventional methods used to drain lymphoceles are invasive and can be associated with complications. Laparoscopic drainage of posttransplant lymphoceles provides a safer alternative.
Collapse
Affiliation(s)
- S Mulgaonkar
- Department of Nephrology, St. Barnabas Medical Center, Livingston, NJ
| | | | | | | | | | | | | | | | | |
Collapse
|